TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Ondine Biomedical, Inc. ( (GB:OBI) ).
Ondine Biomedical Inc. has announced the launch of a pilot program for its Steriwave nasal photodisinfection system at the ABC Medical Center in Mexico City, marking its first hospital deployment in Mexico. This initiative aims to reduce surgical site infections and healthcare-associated infections, addressing the critical challenge of antimicrobial resistance in Mexico’s private healthcare sector, which is pivotal for high-income citizens and medical tourism.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, aimed at preventing and treating infections, including those caused by multidrug-resistant organisms. The company offers a range of investigational products based on its proprietary technology, with approvals in several countries and ongoing clinical trials in the US.
Average Trading Volume: 214,876
Technical Sentiment Signal: Buy
Current Market Cap: £59.97M
Find detailed analytics on OBI stock on TipRanks’ Stock Analysis page.